R1 Pushes Payer Intelligence Upstream With Phare UM

R1's latest Phare OS expansion is more than a utilization-management launch. It is another sign that revenue cycle AI is moving from automating downstream transactions to influencing decisions before the claim exists.

R1 is extending Phare OS into utilization management

R1 announced Phare Utilization Management (Phare UM) on September 16, extending Phare OS into utilization management with an AI-enabled system designed to continuously evaluate patient encounters from admission through discharge.

The product combines clinical evaluation with payer-specific risk. R1 says Phare UM uses Phare Intelligence for clinical evaluation, then layers in payer-specific risk through its Payer Atlas and calibrates recommendations to a health system's clinical policies, payer mix and denial tolerance.

From retrospective review to pre-bill decisioning

Traditional utilization-management workflows can require teams to work through queues and manually assemble clinical and payer context. R1 is positioning Phare UM as a connected decision layer that reviews 100% of cases, assesses denial likelihood, identifies documentation gaps and prioritizes cases that warrant human attention.

R1 says the system keeps clinical judgment at the center of the process. Utilization-management teams receive prioritized worklists and evidence-based recommendations rather than handing the underlying status decision entirely to automation.

That distinction matters. The product is not simply another task bot. R1 is trying to use its clinical, payer and historical outcome data to determine where human expertise should be applied before reimbursement risk becomes a downstream problem.

The data advantage is the bigger story

R1 says it processes more than 1.2 billion payer transactions annually and works with 1,000 healthcare providers, including 95 of the top 100 U.S. health systems. Phare UM illustrates how that operating scale can potentially be turned into a product advantage: historical observations of payer outcomes can inform recommendations earlier in the patient and financial journey.

In a sample assessment for one customer, R1 said Phare UM found that approximately 65% of observation encounters should have been billed as inpatient status. That is a company-reported assessment, not a broadly validated industry benchmark, but it shows the economic problem R1 is targeting: status accuracy, revenue leakage and avoidable medical-necessity denials.

The Guthrie Clinic is among the first health systems adopting Phare UM.

Revenue cycle AI is moving upstream

The pattern extends beyond utilization management. The most consequential RCM automation increasingly sits before final billing: prior authorization, clinical documentation, coding, patient status and payer-specific risk identification.

That changes the competitive question for RCM technology. Automating more downstream work still matters. But vendors with enough payer, clinical and outcome data may be able to predict which downstream problems are forming and intervene earlier.

R1 describes Phare OS as a pre-bill architecture spanning authorization, utilization review, documentation and coding. Phare UM makes the strategy clearer: connect those workflows around a shared intelligence layer rather than treat each as an isolated automation point.

What RCAI is watching

The next question is evidence at scale. RCAI will be watching for health-system case studies showing changes in observation-to-inpatient status accuracy, medical-necessity denial rates, physician-advisor workload, cost-to-collect and reimbursement—not just the percentage of cases reviewed by AI.

If those outcomes materialize, utilization management could become an important proof point for a broader shift: revenue cycle systems moving from workflow automation toward payer-aware decision infrastructure.